Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | DDO | Q99489 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.32 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | ESRRB | O95718 | 1/20 | 0.31 |
| ▸ | ESRRA | P11474 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889012 | 0.77 | GABRA1 (0.40) | GABRA1GABRB2KDM4EALDH1A1LMNA | |
| SCHEMBL1416395 | 0.74 | TRPM4 (0.41) | ALOX15KDM4EALDH1A1LMNA | |
| SCHEMBL19732604 | 0.74 | ALOX5 (0.40) | ALOX15KDM4EALDH1A1LMNAATM | |
| SCHEMBL5146256 | 0.71 | ALDH1A1 (0.39) | ALOX15KDM4EALDH1A1LMNAESR2 | |
| SCHEMBL19732775 | 0.70 | EP300 (0.43) | ALOX15KDM4EALDH1A1LMNA | |
| SCHEMBL3959232 | 0.69 | NQO2 (0.55) | GABRA1GABRB2KDM4EALDH1A1ESR1 | |
| SCHEMBL6632432 | 0.69 | MPL (0.44) | ALOX15ALDH1A1 | |
| SCHEMBL10337449 | 0.68 | GABRA1 (0.48) | GABRA1GABRB2KDM4ELMNAHMGB1 | |
| SCHEMBL5746244 | 0.67 | HTT (0.36) | KDM4EALDH1A1LMNA | |
| SCHEMBL5681182 | 0.67 | GABRA1 (0.46) | GABRA1GABRB2ALOX15KDM4EDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1285914-B1 | Nr1h4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1423370-A4 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1423113-A4 | NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1423111-A4 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-20070010562-A1 | Nr1h4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2007-01-11 | — | — | US | disclosed |
| US-7098336-B2 | FXR NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2006-08-29 | — | — | US | disclosed |
| US-20060148876-A1 | Nr3b1 nuclear receptor binding 3-substituted pyrazoles | PHENEX PHARMACEUTICALS AG (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1536799-B1 | NOVEL 2-AMINO-4-OXOQUINAZOLONES AS LXR NUCLEAR RECEPTOR BINDING COMPOUNDS WITH PARTIAL AGONISTIC PROPERTIES | PHENEX PHARMACEUTICALS AG (DE) | 2006-05-10 | — | — | EP | disclosed |
| US-7034046-B2 | NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2006-04-25 | — | — | US | disclosed |
| WO-2006002022-A2 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF HYPERGLYCEMIA | IMMUSOL INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| US-5916899-A | SOLID PHASE SYNTHESIS, REACTING PROTECTED AMINO ACID WITH SOLID SUPPORT; FORMING IMINE BY REACTION WITH ALDEHYDE, CYCLIZATION WITH ANHYDRIDE, CLEAVAGE AND DEPROTECTION. | TREGA BIOSCIENCES, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0923734-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5874443-A | BIOSYNTHESIS | TREGA BIOSCIENCES, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| US-5840500-A | OPIOD RECEPTORS AS ANALGESICS AND CENTRALLY ACTING PAIN KILLERS | TREGA BIOSCIENCES, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0863877-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | disclosed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010562-A1 | Nr1h4 nuclear receptor binding compounds | NR1H4, NR1H2, NR1H3 | GABRA1 236/4885GABRB2 251/4885ALOX15 2268/4885 |
| US-20060148876-A1 | Nr3b1 nuclear receptor binding 3-substituted pyrazoles | NR0B1, NR0B2, NR4A3 | GABRA1 193/4885GABRB2 118/4885ALOX15 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.